UCLA's Kidney Cancer Program is a world-renowned kidney cancer treatment program, dedicated to providing the highest quality of patient care, research, training and education of kidney cancer for the past 21 years, and is affiliated with the Institute of Urologic Oncology and the Jonsson Comprehensive Cancer Center.
UCLA's Kidney Cancer Program has long utilized a pioneering multidisciplinary approach to treating kidney cancer patients that includes urologists, medical oncologists, radiation oncologists, pathologists, radiologists and clinical trial nurses that allows for specialized perspectives for deciding upon the best option for each individual patient.
UCLA urologist, Karim Chamie, MD, MSHS, presented a live-streaming webinar to discuss new cancer treatments that do not require the unnecessary removal of the kidney or bladder.
The UCLA Kidney Cancer Program prides itself on the achievements made in its state-of-the-art research and translational laboratory. Our highly experienced and dedicated basic science researchers work diligently to develop new, more effective treatments for kidney cancer and have pioneered numerous medical advances.
Kidney Cancer Program Achievements >
For decades, UCLA’s Kidney Cancer Program has prided itself on being able to offer patients access to ground-breaking experimental drugs in its Clinical Trials Program that allows patients to receive tomorrow’s approved drugs today. Until such time as a cure for this disease is found, the primary objective is focused on providing first-rate care for our patients, while making it possible for them to carry on a high quality of life.
About Kidney Cancer
According to the American Cancer Society, an estimated 58,240 people in the United States will be diagnosed with kidney cancer (35,370 men and 22,870 women) and about 13,040 people will die from this disease. As with all cancers, early diagnosis of kidney cancer dramatically improves the chance for survival. Although the prognosis is relatively poor for kidney cancer that is advanced (metastasized), promising new treatments for kidney cancer are improving the outlook for patients.
Most people have two kidneys.
Within this fascia is a layer of fat that surrounds the kidney. The kidney has a thin outer capsule (analogous to the red external layer of an apple). The primary vein that drains the kidney (renal vein) merges with the vein that takes blood to the heart (vena cava). The term "renal" means pertaining to the kidney.
The main function of the kidneys is to produce urine. However, the kidney accomplishes many other important functions during urine production. By adjusting the composition of the urine, the kidney regulates the body's electrolytes (e.g. sodium, potassium, calcium, magnesium, etc.), regulates the body's fluid balance, regulates the body's acid-base balance and eliminates certain waste products made by the body.
When the kidneys are damaged or a significant portion of kidney tissue is removed, its normal processes may be impaired. In most cases, mild to moderate impairment causes very minor problems. In cases when kidney function is severely impaired, dialysis may be required.
Treatment Options >
Renal Kidney Cancer
Renal Cell Carcinoma (RCC) is the most common type of kidney cancer, accounting for approximately 85% of all malignant kidney tumors. In RCC, cancerous (malignant) cells develop in the lining of the kidney tubules and grow into a mass called a tumor. Like many other cancers, the growth begins small and grows larger over time. RCC typically grows as a single mass. However, there are cases where a kidney may contain more than one tumor, or tumors are found in both kidneys at the same time.
Sub-Types of Renal Cell Carcinoma (RCC):
There are five main sub-types of renal cell carcinoma that are identified by examining the tumor under a microscope: clear cell, papillary, chromophobe, collecting duct and "unclassified."
More about sub-types of renal cell carcinoma (RCC) >
RCC accounts for about 90% of malignant kidney tumors. Less common types of cancerous tumors include transitional cell carcinomas, Wilms tumors and renal sarcomas.
About transitional cell carcinoma and benign kidney tumors >
Studies have shown that certain lifestyle, environmental and heredity factors increase the risk of developing renal tumors. Although we do not know all the causes of kidney cancer, the following factors may increase the risk of developing this disease:
Meet Our Doctors >
The Department of Urology at UCLA is one of the most progressive and comprehensive urology programs in the country. Our faculty members work side by side with research scientists for new cures and treatments for kidney cancer.